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Introduction {#sec001}
============

Currently, more than 380 million people worldwide suffer from diabetes and this number is expected to double by 2035 \[[@pone.0235335.ref001]\]. Diabetes significantly enhances the risk of developing cardiovascular disease, which remains the leading cause of mortality in western countries \[[@pone.0235335.ref002]\]. Diabetes mellitus is responsible for the appearance of several microvascular and macrovascular complications such as coronary heart disease and ischemic strokes. Diabetic patients also exhibit a two- to three-fold increase in the risk of heart attacks and strokes \[[@pone.0235335.ref003]\]. Oxidative stress and oxidative modifications of proteins represent deleterious phenomena that have been implicated in the promotion of diabetic complications \[[@pone.0235335.ref002]\]. Oxidative stress was defined as an imbalance between oxidants such as reactive oxygen species (ROS) and antioxidants in favour of the oxidants, leading to a disturbance of redox signalling and molecular damage \[[@pone.0235335.ref004]\]. Chronic hyperglycemia in diabetes pathology leads to enhanced oxidative stress and damage to proteins such as glycation. This phenomenon is linked to the non-enzymatic attachment of a glucose molecule or derivatives to a free primary amine residue. Amadori rearrangement of the glycated protein gives rise to a heterogeneous class of deleterious compounds termed advanced glycation end-products (AGE) \[[@pone.0235335.ref005]\]. Glycation processes are enhanced in diabetics and affect mainly long half-life circulating proteins in particular hemoglobin \[[@pone.0235335.ref005]\]. Glycated hemoglobin (HbA1c) analysis is a clinical test routinely used to determine blood glucose exposure over a long period (weeks/months) in diabetics. Circulating glycated proteins exhibit altered structure and function and may play a pivotal and causative role in diabetes-associated vascular complications \[[@pone.0235335.ref006],[@pone.0235335.ref007],[@pone.0235335.ref008]\].

Human erythrocytes represent the most abundant and one of the most specialized cells in the body and their unique structural feature is constituted by the absence of nuclei, mitochondria and ribosomes \[[@pone.0235335.ref009]\]. The main function of erythrocytes is to transport of oxygen (O~2~) through the human circulatory system \[[@pone.0235335.ref010]\]. Their role in oxygen transport and the presence of heme iron result in the formation of high levels of oxidizing radicals in erythrocytes \[[@pone.0235335.ref010]\]. To avoid oxidative stress, oxidizing radicals can be "detoxified" by antioxidant enzymes such as superoxide dismutase, catalase and glutathione peroxidase, which are commonly found in erythrocytes \[[@pone.0235335.ref010]\]. When oxidative stress occurs, oxidised proteins may be degraded by the 20S proteasome system, which was only recently described in erythrocytes \[[@pone.0235335.ref011],[@pone.0235335.ref012]\]. Erythrocytes play an active role in the development of chronic vascular diseases \[[@pone.0235335.ref013]\]. They constitute the main solid particles present in blood that can 'squeeze' through narrow vessels thanks to the high deformability of their membrane. Erythrocytes are therefore the main blood component in contact with endothelial cells. Very recently, a direct relationship has been established between the erythrocyte width and coronary artery disease rate \[[@pone.0235335.ref014]\]. During atherosclerosis, a common complication in diabetic patients, erythrocytes can reach the atherosclerotic plaque after healed ruptures and thrombus formation. Rupture of micro vessels causing intraplaque hemorrhages can also bring erythrocytes into the plaque \[[@pone.0235335.ref015]\]. Very recently, high erythrocyte mortality levels (eryptosis) associated with enhanced phagocytosis by smooth muscle cells were found to be a promoting factor of oxidative stress in early-stage atheroma in people \[[@pone.0235335.ref016]\].

Despite the well-established implications of oxidative damage in diabetes disorder development and the active role of erythrocytes in vascular complication, very little is known about the impact of glycation on the structure of erythrocytes, their redox status and capacity to be phagocytosed by endothelial cells. Here, we hypothesized that glycation impairs erythrocyte structure, redox status, hemolysis sensibility and enhances its phagocytosis by cultured human endothelial cells. In light of the results presented in this paper we believe that enhanced glycation-mediated modification of erythrocytes and endocytosis by endothelial cells could play an important role in the development of the diabetes-linked vascular complications.

Materials and methods {#sec002}
=====================

Erythrocyte preparations {#sec003}
------------------------

Experiments involving human erythrocytes were approved by our institutional review board at Centre Hospitalier Universitaire (La Réunion, France). Samples were obtained from the Alb-Ox ERMIES an ancillary, pilot study of ERMIES (NCT01425866). All data were analyzed anonymously.

Blood from healthy volunteers with informed consent was collected in EDTA tubes (BD vacutainer®). After centrifugation, erythrocytes were washed 3 times with a sterile isotonic solution (NaCl 0.15 M, pH 7) and suspended to 20% hematocrit in sterile PBS. This solution was subsequently diluted with glucose stock solutions made in PBS to form incubation mixtures of erythrocytes with 0, 5, 25 and 137 mmol/l glucose (corresponding to 0, 0.9, 4.5 and 25 mg/mL glucose, respectively). After 5 days of incubation at 37°C, erythrocytes were washed 3 to 4 times with 0.15 M NaCl. For specific studies, erythrocytes from 12 type-2 diabetic individuals (HbA1c (%) = 11 ± 2.6) and from 9 non-diabetic individuals of the same age (HbA1c (%) = 4.4 ± 1) were obtained from the Alb-Ox ERMIES an ancillary, pilot study of ERMIES (NCT01425866). Erythrocytes were isolated as previously described and then suspended to 10% hematocrit in sterile PBS before incubation at 37°C for 5 days. Erythrocyte preparations were either directly analysed by FACS and ektacytometry, lysed with an equivalent volume of distilled water (enzymatic activities, redox status) or subjected to "ghost" preparation (membrane oxidative damage). In lysates, optical density was measured at 280 nm and protein concentration was calculated according to a standard curve of hemoglobin (50--500 μg) and expressed in μg per μL. In membrane preparation, protein concentrations were measured using Bradford assay.

HbA1c (%) level {#sec004}
---------------

Measurements were performed on our diluted erythrocyte preparations by using a high-pressure liquid chromatography method performed on an automated Hemoglobin analyser (D-10, Biorad) at the hospital of Saint Paul (La Réunion, France).

Mass spectroscopy for average molecular mass determination {#sec005}
----------------------------------------------------------

Glycation of both α and β hemoglobin subunits was analysed by matrix-assisted desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) for mass shift determination as previously described \[[@pone.0235335.ref017]\]. Mass spectra were obtained in three independent experiments. On each spectrum, the four main peaks for α and β haemoglobin subunits and their glycated forms were identified. For each peak, the mass (m/z) and Δmass between non-glycated and glycated subunits were obtained. Relative intensity of each peak was calculated as follow: % glycation = (intensity glycated-hemoglobin / intensity hemoglobin) x 100.

5-hydroxymethylfurfural level {#sec006}
-----------------------------

The thiobarbituric acid (TBA) assay was used for 5-hydroxymethylfurfural (5-HMF) quantification in our different preparations according to the protocol detailed in Murtiashaw et al. \[[@pone.0235335.ref018]\]. Briefly, 1 ml of diluted erythrocytes was hydrolysed at 100°C for 1 h after addition of 0.5 ml of 0.3 N oxalic acid. After cooling to RT, 0.5 ml of 40% trichloroacetic acid was added and thoroughly mixed before centrifugation for 15 min at 3000 g. Then, 0.5 ml of 0.05 M TBA was added to 0.4 ml of supernatant and the mixture was incubated at 40°C for 30 min. The absorbance was read at 443 nm. The 5-HMF concentration was determined by using its molar extinction coefficient (4.10^8^) and expressed as mmol of 5-HMF per milligram of protein.

Early glycation product determination {#sec007}
-------------------------------------

Fluorescein boronic acids (Flu-BA) were used to detect early glycation products (EGP) in our erythrocyte preparations. Flu-BA was prepared following the protocols detailed in Pereira Morais et al. \[[@pone.0235335.ref019]\]. Boronic acids specifically interact with fructosamine-modified proteins via interaction with the cis-1,2-diol containing adducts \[[@pone.0235335.ref019]\]. This probe was recently used to quantify carbohydrate modifications in tissue extracts \[[@pone.0235335.ref020],[@pone.0235335.ref021]\].

Prior to flow cytometry analysis, erythrocyte preparations (approximately 10^6^ cells) were incubated with 25 μM of Flu-BA or fluorescein in binding buffer (BioLegend) for 30 min at RT. After incubation, cells were pelleted by centrifugation (1000 rpm, 5 min) and supernatant was discarded, and labelled cells were resuspended in PBS. Fluorescence was measured by FACS (Beckman Coulter\'s CytoFLEX and Cytexpert software) with an excitation and emission wavelengths of 488 nm and 530 nm, respectively. The level of early glycation products were determined after mean fluorescence normalization of erythrocytes probed with fluorescein only and expressed as a percentage relative to the control (non glycated erythrocytes G0).

Free radical-induced hemolysis test {#sec008}
-----------------------------------

The capacity of erythrocyte preparations to resist lysis induced by an oxidative stress was investigated by using the *in vitro* free radical-induced blood hemolysis assay. Hemolysis was induced using a water-soluble free radical generator, 2,2'-azo-bis 2-aminodinopropane (AAPH, Sigma). 135 μL of diluted erythrocyte preparations (approximately 10^8^ erythrocytes) were added to each well of a 96-well plate. Hemolysis was started by adding 40μL of 0.5 M AAPH to each well and the turbidimetry at 450 nm was recorded every 10 minutes using a temperature controlled microplate reader at 37°C (Fluostar, BMG Labtech). For each condition, the time to 50% of maximal hemolysis (HT50) was determined in triplicate. In other work, the measurement of HT50 was shown to be very reproducible: 1.32% and 3.85% intra- and inter-assay coefficients, respectively \[[@pone.0235335.ref022]\].

Enzymatic activities {#sec009}
--------------------

SOD activity was measured by monitoring the rate of acetylated cytochrome c reduction by superoxide radicals generated by the xanthine/xanthine oxidase system as published in \[[@pone.0235335.ref023]\]. Measurements were performed using the reagent buffer (xanthine oxidase, xanthine (0.5 mM), cytochrome c (0.2 mM), KH~2~PO~4~ (50 mM), EDTA (2 mM), pH 7.8) at 25°C. The kinetics of cytochrome c reduction were monitored by spectrophotometry at 560 nm. SOD activities calibrated relative to a standard curve of SOD up to 6 unit/mg.

The catalase activity assay was carried on 40 μg of protein lysate in 25 mM Tris--HCl (pH 7.5), as recently described \[[@pone.0235335.ref023]\]. Blanks were measured at 240 nm just before adding 80 μL of H~2~O~2~ (10 mM final) to start the reaction. The kinetics of H~2~O~2~ reduction were monitored by measuring the absorbance every 5 s at 240 nm for 1 min and catalase activity was calibrated relative to a standard curve of increasing amount of catalase between 12.5 and 125 units/ml. Catalase activity was expressed as international catalytic units per mg of protein.

Chymotrypsin-like activity of the proteasome was assayed using the fluorogenic peptide (Sigma-Aldrich, St Louis): Suc-Leu-Leu-Val-Tyr-7-amido-4-methylcoumarin (LLVYMCA at 25 mM), as described previously \[[@pone.0235335.ref024]\].

Peroxidase activities of cell lysates were assessed according to the method of Everse *et al* \[[@pone.0235335.ref025]\]. A reaction mixture was prepared with 50 mM citrate buffer, 0.2% o-dianisidine and samples diluted 1/100. The reaction was initiated by adding 20 mM H~2~O~2~. Peroxidase activity was determined by measuring the absorbance at 450 nm at 25°C for 3 min. Peroxidase activity was expressed as international catalytic units per mg of protein.

Dot-blots {#sec010}
---------

Four microliters of erythrocyte lysate (approximately 20 μg of proteins) were spotted onto a dry nitrocellulose membrane. The membrane was air-dried for 5 minutes and total protein was stained using Ponceau red dye. The membrane was initially blocked with PBS/Tween 20 0.1% (v/v)/ milk 5% for 3 hours at room temperature and then sequentially probed for another 3 hours with a primary antibody directed against 4-HNE (1:1000; ab46545; Abcam, Cambridge MA) or rabbit anti AGE antibody (Abcam, Ab23722). This was followed by secondary antibody incubation for at least 1 hour (1:2000; Peroxidase AffiniPure Goat Anti-Rabbit IgG (H+L); Jackson Immunoresearch Laboratories Inc; 111-035-003). Between each step, membranes were washed three times with PBS/Tween 20 0.1% (v/v). Detection was performed using the enhanced chemiluminescence reagent (ECL®, GE Healthcare). Signal intensities were quantified using the freeware ImageJ (version 1.32j) available from the internet website: <http://rsb.info.nih.gov/ij/>.

Endothelial cell culture and stimulation {#sec011}
----------------------------------------

The human endothelial EA.hy926 cell line was obtained from the American tissue culture collection (CRL-2922) and was cultured in DMEM supplemented with 10% Fetal Bovine Serum (FBS), penicillin (100 units/ml), streptomycin (100 μg/ml), L-glutamine (2 mM) and HAT (hypoxanthine 100 μmol/L; aminopterin 0.4 μmol/L and thymidine 16 μmol/L). Cells were grown in a 5% CO~2~ incubator at 37°C in a humidified atmosphere. Approximately 100 000 cells were plated in 24 cell plates. When cells reached confluency, they were treated in the absence (control PBS) or presence of 71 μl/cm² of the different erythrocytes preparations for 24 h. Internalized erythrocytes were detected using the 2,7-diaminofluorene (DAF) reagent which quantifies the pseudo-peroxidase activity of RBC hemoglobin. After 24-hours of incubation with erythrocytes, endothelial cells were washed 3 times with PBS and treated with water for 3 minutes to induce lysis (by hypotonic shock) of any fixed erythrocytes at the cellular membrane surface and supernatant was discarded.

Endothelial cells were then lysed with PBS/Triton X100 for 3 minutes to release the cytosolic fraction containing internalized erythrocytes and their hemoglobin. DAF solution was prepared extemporaneously by dissolving 10 mg of DAF reagent in 10 ml of tris HCl 0.2 N with 9% acetic acid supplemented with 20 μl of 30% hydrogen peroxide just before use. 100 μl of DAF solution was added to 40 μl of cytosolic samples previously transferred to a 96-well plate. Optical density (OD) was measured at 620 nm. Internalized erythrocytes were quantified relative to calibration erythrocyte standards (27--5760 cells/μl) and results were expressed as erythrocyte number.

Flow cytometry assays {#sec012}
---------------------

Erythrocyte shape, eryptosis evaluation and intracellular reactive oxygen species (ROS) production in our different erythrocyte preparations were measured by flow cytometry using Beckman Coulter\'s CytoFLEX and Cytexpert software. A specific erythrocyte cell population was selected by gating and could be characterized by its typical location in a forward scatter (FSC) *versus* a side scatter (SSC) parameter graph. For phosphatidylserine exposure determination, erythrocytes were incubated with 2 μg/ml Annexin V-FITC in binding buffer (BioLegend) for 30 min at RT before flow cytometry analysis. Annexin V protein exhibits a high affinity for phosphatidylserine (PS) and was measured with an excitation wavelength of 488 nm and an emission wavelength of 530 nm. For evaluation of intracellular reactive oxygen species (ROS) production, erythrocytes were incubated with 2 μM of the fluorescent probe dihydroethidium (DHE; Sigma-Aldrich, D7008) or dichlorodihydrofluoresceindiacetate (DCFH-DA; Sigma-Aldrich, D6883) for 30 min at RT.

Ektacytometry {#sec013}
-------------

The determination of erythrocytes membrane deformability was performed using an ektacytometer (LORCCA MaxSis, Mechatronics, The Netherlands) which measures the elongation of red blood cells at increasing shear stress. Red blood cells suspended at 10% hematocrit were diluted 200 times in an iso-osmolar solution of polyvinylpyrrolidone buffer (PVP, viscosity 28.6 mPa/s). Deformation was expressed as an elongation index (EI) was calculated for 19 shear-stresses between 0.30 and 80 Pa (increasing rotation speed) as follows: EI = (A-B) / (A+B), where A and B represent the length and the width of the ellipsoid diffraction pattern, respectively. The deformability curve was obtained by plotting the calculated values for EI versus the shear stress \[[@pone.0235335.ref026]\].

Statistical analysis {#sec014}
--------------------

Data are expressed as the mean ± standard deviation (SD) or as the mean ± standard error of the mean (SEM) from at least three independent experiments performed in triplicate. Statistical analyses were performed with Prism (GraphPad Software Inc., San Diego, CA, USA). Statistical significance was determined using the Student's t-test or one-way ANOVA followed by Dunnett's test, with a p-value \< 0.05 required for significance.

Results {#sec015}
=======

Impact of in vitro glycation on erythrocyte morphology and redox status {#sec016}
-----------------------------------------------------------------------

Experiments were designed to determine whether short-term incubation of erythrocytes with increasing concentrations of glucose may affect their morphology and redox status.

To characterize the glycation level of our erythrocyte preparations, the percentage of HbA1c and the 5-HMF concentration were measured in the lysates of our different preparations ([Table 1](#pone.0235335.t001){ref-type="table"}). A significant increase in HbA1c percentage was observed in erythrocytes incubated with 137 mM of glucose (p\<0.05) compared to erythrocytes incubated in the absence of glucose (G0). Interestingly, the value obtained for G137 erythrocytes (7%) is highly similar to HbA1c values observed in diabetic patients. Indeed, 6.5% in HbA1c corresponds to the threshold used to diagnose persons with diabetes \[[@pone.0235335.ref027]\]. Similar results were observed with the 5-HMF concentrations in the different glycated erythrocyte preparations ([Table 1](#pone.0235335.t001){ref-type="table"}). This intermediate formed from carbohydrates such as glucose is a good indicator of protein glycation \[[@pone.0235335.ref028]\].

10.1371/journal.pone.0235335.t001

###### *In vitro* incubation with high glucose concentration significantly enhances erythrocyte glycation.

The impact of erythrocyte incubation in the presence of enhanced glucose concentration on the percentage of glycated hemoglobin (% HbA1c), the 5-hydroxymethylfurfural and the early glycation product (EGP) levels were determined as described in material and method section. GX corresponds to erythrocytes incubated with X mM glucose and G0 corresponds to erythrocytes incubated in the absence of glucose. Data are expressed as mean ± SEM (n = 6 to 8 independent replicates) and statistical analyses were performed using One-way ANOVA followed by Dunnett's test. \*p\<0.05, \*\*p\<0.01 in comparison with G0.

![](pone.0235335.t001){#pone.0235335.t001g}

                     G0     G5   G25    G137                                             
  ------------------ ------ ---- ------ ------- --- ------ ------- --- ------ ------ --- ----------
  **HbA1c (%)**      5.22   ±    0.4    5.18    ±   0.4    4.9     ±   0.47   7.06   ±   1.65\*
  **5-HMF (% G0)**   100    ±    14.4   97.2    ±   10.1   102     ±   14.8   155    ±   31.5\*\*
  **EGP (% G0)**     100    ±    19.3   129.8   ±   14.4   135.3   ±   20.4   457    ±   63.2\*\*

Early glycation product (EGP) accumulation in erythrocyte preparations was evaluated using a specific fluorescent probe (Flu-BA) developed by our group \[[@pone.0235335.ref019]\].

EGP levels determined after fluorescence normalization of erythrocytes probed with fluorescein only are reported in [Table 1](#pone.0235335.t001){ref-type="table"}. A significant increase in EGP accumulation was observed in erythrocytes incubated with 137 mM of glucose (p\<0.01) compared to erythrocytes incubated at G0.

Flow cytometry of fluorescein boronic acid-labelled erythrocytes detected a distinct subpopulation of cells that appeared after treatment with high concentrations of glucose ([Fig 1](#pone.0235335.g001){ref-type="fig"}).

![Early glycation product detection by using fluorescent boronic acids.\
Cytometry analysis of our erythrocyte preparations was performed as described in material and method section. Following probing with fluorescent boronic acids, erythrocyte populations were gated according to cell location in a side scatter (SSC) parameter *vs*. FITC fluorescence. Black arrow evidences the specific population of glycated positive erythrocytes that become predominant when they were incubated with increasing concentrations of glucose.](pone.0235335.g001){#pone.0235335.g001}

To further characterize the glycation level in our erythrocyte preparations, the proportion of glycated forms of both α and β hemoglobin was determined by mass spectrometry. Representative figures of the mass spectra obtained for α- and β -hemoglobin subunits and their glycated forms are presented in the supplementary materials (cf [S1 Fig](#pone.0235335.s002){ref-type="supplementary-material"}). The relative intensity of m/z peaks corresponding to glycated and non-glycated forms for both subunits, and the corresponding percentage of glycation are presented in [Table 2](#pone.0235335.t002){ref-type="table"}. Our results show erythrocytes incubated with 137 mM of glucose are significantly more glycated in both hemoglobin subunits (α and β) than G0 erythrocytes. It is worth noting that for all erythrocyte preparations, the glycated forms of the Hb subunits display a \~200 Da increase in mass. The increase in glycation was also confirmed by significant increases in AGE content in dot blots ([Fig 2A and 2B](#pone.0235335.g002){ref-type="fig"}) and western blots ([Fig 2C and 2D](#pone.0235335.g002){ref-type="fig"}).

![Glycated erythrocytes exhibit an impaired deformability capacity.\
In this figure, G0, G5, G25 and G137 represent the four conditions of incubation to which erythrocytes were subjected: 0, 5, 25 and 137 mmol/l glucose, respectively. (A) Representative AGE dot blot performed on lysate preparations (n = 4); (B) Quantification of AGE signal normalized with Ponceau S signal in the different erythrocyte preparations. Results are expressed as mean ± SEM of 3 to 4 experiments performed independently. ^\#^p\<0.05 *vs*. G5 (Student's t test, n = 3 to 4); (C) Representative AGE western blot performed on lysate preparations (n = 4); (D) Quantification of AGE signal normalized with ponceau red signal in the different erythrocyte preparations. Results are expressed as mean ± SEM of 4 experiments performed independently. \*p\<0.05, \*\*p\<0.01 vs. G0 (Student's t test, n = 4). (E) HT50 was measured by the free-radical hemolysis test as described in method section. Results are expressed as mean ± SEM of 5 to 8 experiments performed independently. \*p\<0.05, \*\*p\< 0.01 indicates a significant difference *vs*. G0 (One-way ANOVA followed by Dunnett's test) n = 5 independent analyses; (F) Curves correspond to the elongation index of erythrocytes determined by LORRCA measurement as a function of shear stress intensity (Pa); (G) Histograms correspond to the calculated variation in elongation index (delta EI) reflecting capacity of erythrocytes to deform when submitted to a shear stress ranking from 0 to 80 Pa. Results are expressed as mean ± SEM. \*p\<0.05 indicates a significant difference as compared to G0 (One-way ANOVA followed by Dunnett's test) n = 3 independent replicates.](pone.0235335.g002){#pone.0235335.g002}

10.1371/journal.pone.0235335.t002

###### Characterisation of glycation percentage in the different erythrocyte preparations by mass spectrometry.

Data for the four main peak of the mass spectra corresponding to α-hemoglobin (α-Hb; 15130 Da), glycated α-hemoglobin (g-α-Hb; 15330 Da), β-hemoglobin (β-Hb; 15890 Da), glycated β-hemoglobin (g-β-Hb; 16100 Da) ([S1 Fig](#pone.0235335.s002){ref-type="supplementary-material"}---see supplemental data). G0, G5, G25 and G137 represent the four conditions of incubation to which erythrocytes were subjected: 0, 5, 25 and 137 mmol/l glucose, respectively. Δmass and % glycation were calculated as explained in the methods section. Results are the mean ± SD and statistical analyses were performed using Tukey's post hoc analysis following a significant one way ANOVA: \*\*\*p\<0.001, \*\*p\<0.01, \*p\<0.05 (vs. G0), \#\#\#p\<0.001, \#p\<0.05 (vs. G5).

![](pone.0235335.t002){#pone.0235335.t002g}

  ---------- ------------------ ------------------- ---------------- ------------ ------------------ ------------------------------------
             **α-hemoglobin**                                                                        
             **α-Hb**           **glycated-α-Hb**                                                    
             mass/z             Intensity           mass/z           Intensity    **Δ mass**         **% glycation**
  **G0**     15132.2 ± 3.2      98.9 ± 2.9          15334.1 ± 3.4    46.7 ± 3.8   **201.8 ± 1.2**    **48.4 ± 1.2**
  **G5**     15132.4 ± 3.8      100.0 ± 0.1         15334.8 ± 2.9    48.7 ± 2.9   **202.4 ± 1.2**    **48.6 ± 0.7**
  **G25**    15134.9 ± 2.6      98.3 ± 5.1          15335.5 ± 2.5    50.3 ± 4.0   **200.6 ± 0.9**    **51.2 ± 0.7**
  **G137**   15139.2 ± 3.2      95.2 ± 7.9          15334.0 ± 3.8    54.9 ± 6.4   **194.8 ± 1.9**    **57.8 ± 1.3\*\***^**\#**^
             **β-hemoglobin**                                                                        
             **β-Hb**           **glycated-β-Hb**                                                    
             mass/z             Intensity           mass/z           Intensity    **Δ mass**         **% glycation**
  **G0**     15891.5 ± 3.7      77.5 ± 16.4         16093.1 ± 11.9   50.2 ± 8.2   **201.8 ± 11.5**   **66.6 ± 1.9**
  **G5**     15892.5 ± 4.2      78.6 ± 10.8         16091.7 ± 7.4    52.6 ± 8.4   **201.8 ± 11.5**   **67.0 ± 1.3**
  **G25**    15894.5 ± 3.6      78.3 ± 15.4         16089.0 ± 3.7    54.5 ± 7.8   **194.5 ± 4.2**    **70.0 ± 1.4\***
  **G137**   15897.2 ± 3.6      89.9 ± 12.1         16088.5 ± 3.9    67.1 ± 11    **191.3 ± 3.8**    **74.3 ± 1.2\*\*\***^**\#\#\#\#**^
  ---------- ------------------ ------------------- ---------------- ------------ ------------------ ------------------------------------

The capacity of erythrocytes to resist oxidative stress was examined using *in vitro* free radical-induced blood hemolysis. Results were expressed as the half time of hemolysis (HT50) following our erythrocyte preparations "attack" with a free radical generator (AAPH). Erythrocytes incubated with 5 or 25 mM of glucose (G5, G25) exhibited a significantly higher HT50 compared to G0 ([Fig 2E](#pone.0235335.g002){ref-type="fig"}). This was suggestive of a protective membrane-stabilising effect of low concentrations of glucose which, interestingly, was no longer observed when incubated at 137 mM glucose ([Fig 2E](#pone.0235335.g002){ref-type="fig"}).

Due to their biconcave shape, erythrocytes are able to deform and pass through small vessels like capillaries \[[@pone.0235335.ref009]\]. The deformability of the different erythrocyte preparations was analysed using the ektacytometry method and results are displayed in [Fig 2F and 2G](#pone.0235335.g002){ref-type="fig"}. Changes in the elongation index revealed a loss of cellular deformability in response to increasing shear stress when erythrocytes were incubated with increasing concentrations of glucose. A significant decrease of deformability was observed in glycated erythrocytes compared to erythrocytes incubated in the absence (G0) or presence of low concentration of glucose (G5). These data clearly indicate that the glycation phenomenon induced by the hyperglycemic incubations renders erythrocytes less deformable (about four times less) and more rigid than erythrocytes incubated under low glycemic conditions. It is worth noting that impaired deformability of glycated erythrocytes was also observed under low shear stress conditions (3 Pa), which are similar to those that can be encountered under standard physiological conditions \[[@pone.0235335.ref029]\].

Erythrocyte morphology and deformability were subsequently investigated in order to get further insights into erythrocyte fragility. Flow cytometry was used to determine the relative size of our different erythrocyte preparations. By using the FSC and SSC parameters, each preparation containing a mix of erythrocytes was analysed and specific populations were gated according to cell size and granularity. We observed the formation of an additional erythrocyte population (highlighted by an arrow in [Fig 3A](#pone.0235335.g003){ref-type="fig"}), which became dominant when incubated at higher concentrations of glucose. This potentially represents a population of erythrocytes engaged in an accelerated aging process induced by the hyperglycemic treatment \[[@pone.0235335.ref030]\].

![Glycation alters erythrocyte morphology.\
Cytometry analysis of our erythrocytes preparation was performed as described in material and method section. GX corresponds to erythrocytes incubated with X mM glucose and G0 corresponds to erythrocytes incubated in the absence of glucose. (A) Erythrocyte populations were gated according to cell location in a forward scatter (FSC) versus a side scatter (SSC) parameter. Black arrow evidences the specific population of glycated altered erythrocytes that become predominant when they were incubated with increasing concentrations of glucose. (B) SSC parameters of our erythrocytes preparation were performed as described in material and method section \*\*p\<0,01 indicates a significant difference *vs*. G0 (Student's t test).](pone.0235335.g003){#pone.0235335.g003}

Hyperglycemic conditions are known to be associated with increased ROS production (5). Therefore, we evaluated the impact of *in vitro* glycation on erythrocyte redox status. The impact of *in vitro* glycation on erythrocyte redox balance was first determined by the analysis of intracellular ROS formation using a specific fluorescent probe in cell lysate. The dihydroethidium molecule (DHE) can penetrate erythrocytes and emit fluorescence when oxidised by free radicals. Increase in DHE fluorescence in erythrocytes was observed when incubated with increasing concentrations of glucose ([Fig 4A](#pone.0235335.g004){ref-type="fig"}). This enhanced intracellular free radical formation reached our significance threshold in erythrocytes glycated with 137 mM of glucose (p\<0.01, *vs*. G0). The levels of the oxidative damage-indicating biomarker 4-HNE were significantly higher in erythrocytes that were glycated with 25 or 137 mM of glucose compared to those exposed to 5 mM of glucose ([Fig 4B and 4C](#pone.0235335.g004){ref-type="fig"}).

![Enhanced oxidative stress and damages in glycated erythrocytes.\
In this figure, G0, G5, G25 and G137 represent the four conditions of incubation to which erythrocytes were subjected: 0, 5, 25 and 137 mmol/l glucose, respectively. (A) Intracellular ROS formation levels in erythrocyte preparation was determined using DHE probe by cytometry. Results are expressed as mean ± SEM (n = 4), \*\*p\<0.01 indicates a significant difference *vs*. G0 (one way ANOVA followed by Dunnet's test). (B) 4-HNE dot blot image is representative of four dot blot experiments. (C) 4-HNE signal quantification was expressed as mean ± SEM (n = 4), \*p\<0.05 (*vs*. G0), ^\#^p\<0.05, ^\#\#^p\<0.01 (*vs*. G5) using Student's t test. (D) Phosphatidyl serine (PS) exposure in erythrocytes preparations was evaluated by cytometry as described in method section. Data are expressed as mean ± SEM, \*p\< 0.05, \*\*\*p\< 0.001 *vs*. G0 (one-way ANOVA followed by Dunnett's test, n = 4). (E) Internalized red blood cell in cultured EA.hy926 cell lines was determined by DAF assay and are expressed in arbitrary unit as mean ± SEM (n = 3), \*p \< 0.05, \*\*p\< 0.01 (one-way ANOVA followed by Dunnett's test).](pone.0235335.g004){#pone.0235335.g004}

In order to gain further insight into the redox status of our erythrocyte preparations and the origin of enhanced ROS formation and oxidative damage in glycated erythrocytes, antioxidant enzyme and proteasome activities were measured ([Table 3](#pone.0235335.t003){ref-type="table"}). Whilst SOD and catalase activities appeared not to be significantly different in our erythrocyte preparations, a significantly reduced peroxidase activity was measured in erythrocytes that were incubated with 137 mM of glucose (-33%, p\<0.05 *vs*. G25). This reduced peroxidase activity could explain the enhanced ROS formation in G137 erythrocytes. Similarly, a significant reduction of the chymotrypsin-like activity of the proteasome was measured in G137 erythrocytes (-74%, p\<0.05 *vs*. G5).

10.1371/journal.pone.0235335.t003

###### Effect of glycation on erythrocyte enzymatic activites involved in redox balance and in oxidised protein degradation.

Catalase, superoxide dismutase, peroxidase and chymotrypsine-like activity of the proteasome (LLVY). Enzymatic activities were determined as described in the material and methods section. G0, G5, G25 and G137 represent the four conditions of incubation to which erythrocytes were subjected: 0, 5, 25 and 137 mmol/l glucose, respectively. Results are expressed as mean ± SD (n = 4 to 9) and statistical analyses were performed using Tukey's post hoc analysis following a significant one way ANOVA: \* effect of erythrocyte glycation (vs. G 5): \* p\<0.05. \#p\<0.05 (vs. G25).
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                              G0    G5   G25   G137                                     
  --------------------------- ----- ---- ----- ------ --- ---- ----- --- ---- ----- --- --------
  **SOD** AU/mg prot          100   ±    28    109    ±   42   121   ±   40   140   ±   73
  **Catalase** AU/mg prot     100   ±    27    105    ±   30   146   ±   53   131   ±   82
  **Peroxidase** AU/μg prot   100   ±    20    88     ±   31   106   ±   49   71    ±   26^\#^
  **LLVY** AU/μg prot         100   ±    10    129    ±   73   110   ±   63   33    ±   37\*

Enhanced intracellular oxidative stress could be a determining signal for glycated erythrocytes to initiate eryptosis, the programmed cell death for anuclear erythrocytes. To confirm this hypothesis, we investigated whether glycated erythrocyte preparations exhibit phosphatidylserine exposure, which is a measure of eryptosis \[[@pone.0235335.ref031]\]. Incubations with 25 mM and 137 mM of glucose lead to a significantly higher phosphatidylserine exposure, in a dose-dependent manner, when compared to erythrocytes incubated in the absence of glucose ([Fig 4D](#pone.0235335.g004){ref-type="fig"}). These results clearly indicate that eryptosis is enhanced in glycated erythrocytes. Phosphatidylserine exposure associated with membrane rigidity appears to be critical factors of red blood cell clearance. Effects of glycated erythrocytes were further investigated by analysing their capacity of being phagocytosed by the human endothelial EA.hy926 cell line.

[Fig 4E](#pone.0235335.g004){ref-type="fig"} shows that glycation of erythrocytes with high glucose concentration (25 mM and 137 mM) induced their phagocytosis by endothelial cells, as illustrated by high levels of internalized red blood cells. These results can be related to the enhanced eryptosis of red blood cells when glycated. Endothelial cells viability did not seem to be affected by the enhanced phagocytosis of glycated erythrocytes.

*In vivo* modifications of erythrocytes in diabetic vs non-diabetic individuals {#sec017}
-------------------------------------------------------------------------------

We compared results from our *in vitro* model of glycation, to those of erythrocytes isolated from diabetic or non-diabetic individuals in terms of both morphology and redox status.

Erythrocytes from diabetic patients were significantly less deformable than erythrocytes from non-diabetics ([Fig 5A and 5B](#pone.0235335.g005){ref-type="fig"}). Indeed, the variation of elongation index in response to an increasing shear stress appears to be lower for erythrocytes isolated from diabetic persons compared to non-diabetics. A significant higher SSC was measured for erythrocytes when purified from diabetics (+38% ± 23.4, p\<0.05 *vs*. ND), whereas the FSC value was not impacted (Figs [5C](#pone.0235335.g005){ref-type="fig"} and [S2](#pone.0235335.s003){ref-type="supplementary-material"}). This result is in favour of an altered erythrocyte structure and shape when isolated from diabetics. With respect to the redox status ([Fig 5D](#pone.0235335.g005){ref-type="fig"}), a significant increase in intracellular ROS formation, probed by DHE, was evidenced in erythrocytes that were purified from diabetics (+39%, p\<0.05 *vs*. ND). Similar and significant result was also evidenced by using DCFDA probe ([Fig 5E](#pone.0235335.g005){ref-type="fig"}).

![Erythrocytes from diabetics exhibit altered morphology and enhanced oxidative stress.\
(A) Curves correspond to the elongation index of erythrocytes determined by LORRCA measurement as a function of the shear stress intensity (in Pascal unit). (B) Delta elongation index, results are mean ± SEM (n = 9 ND and 12 D), \*p\<0.05 (Student's t test). (C) Geo mean Side Scatter (SSC) value of erythrocytes analysed by flow cytometry, \*p\<0.05 (Student's t test). (D) Intracellular ROS formation level in erythrocyte evaluated using DHE probe by cytometry, \*p\<0.05 (Student's t test). (E) Intracellular ROS formation in erythrocyte preparation was evaluated using DCFDA probe by cytometry. Results are expressed as mean ± SEM, \*p\<0.05 (Student's t test). (F~~E~~) Phosphatidylserine exposure in erythrocytes preparations was quantified by cytometry as described in method section. (G) Representative AGE dot blot performed on lysate preparations of erythrocytes isolated from diabetic and non-diabetic individuals. (H~~F~~) AGE quantification by dot blot, n = 9 ND and 12 D, \*p\<0.05 (Student's t test).](pone.0235335.g005){#pone.0235335.g005}

Three oxidative parameters were determined in erythrocytes from diabetic and non-diabetic persons. No variation in 4-HNE levels was observed, while a significant increase in AGE formation was seen in erythrocytes from diabetics ([Fig 5F and 5G](#pone.0235335.g005){ref-type="fig"}). In addition, accumulation of advanced oxidation product (AOPP), was found to be higher (+18%) in erythrocytes from diabetics but this increase did not reach significance.

Although catalase and SOD activities appeared not to be significantly different between both groups (ND *vs*. D), a significant reduced peroxidase activity was measured in erythrocytes isolated from diabetic persons ([Table 4](#pone.0235335.t004){ref-type="table"}). This reduction in peroxidase activity, associated with high glucose concentration, could explain the enhanced ROS formation in erythrocytes isolated from diabetic persons. Conversely, the chymotrypsin-like activity of the proteasome appeared to be significantly enhanced in erythrocytes purified from diabetics compared to those from non-diabetics ([Table 4](#pone.0235335.t004){ref-type="table"}).

10.1371/journal.pone.0235335.t004

###### Intracellular enzymatic activities of erythrocytes isolated from non-diabetic and diabetic.

Catalase, superoxide dismutase, peroxidase and proteasome enzymatic activities were determined as described in the section of material and methods. Results are expressed as mean ± SD (n = 9 ND and 12 D), \*P \<0.05 *vs*. ND (Student's t-test).
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                              ND    D                  
  --------------------------- ----- --- ---- ----- --- ------
  **SOD** AU/mg prot          100   ±   25   84    ±   31
  **Catalase** AU/mg prot     100   ±   28   100   ±   33
  **Peroxidase** AU/μg prot   100   ±   14   90    ±   11\*
  **LLVY** AU/μg prot         100   ±   72   161   ±   36\*

Proteasome activity may be activated under moderate oxidative stress \[[@pone.0235335.ref032]\]. *In vivo*, if oxidative stress is higher in erythrocytes from diabetics than from non-diabetics, no variation was measured in term of 4-HNE accumulation. Enhanced oxidative stress in *in vivo* glycated erythrocytes may be significant and moderate enough to trigger proteasome LLVY activation.

Finally, eryptosis in erythrocytes from diabetics or non-diabetics was investigated ([Fig 5H](#pone.0235335.g005){ref-type="fig"}). Erythrocytes from diabetic persons exhibit a tendency for a higher phosphatidylserine exposure than erythrocytes isolated from non-diabetic persons. This is in favour of a triggered eryptosis phenomenon in erythrocytes when *in vivo* glycated.

Discussion {#sec018}
==========

Despite the fact that erythrocytes represent a key player in vascular complications, very little is known about how structure, redox status and capacity of erythrocytes to be phagocytosed by endothelial cells can be affected by glycation. In this study we revealed that *in vitro* glycation renders erythrocytes less deformable and leads to the alteration of their structure. We demonstrated that glycated erythrocytes produce more intracellular ROS and exhibit an altered redox balance. Furthermore, we highlight a potentially higher phosphatidylserine exposure of erythrocytes when glycated. All these characteristics observed in *in vitro* glycated erythrocytes were confirmed to occur *in vivo* when analysing erythrocytes isolated from diabetic patients.

To obtain an *in vitro* model of glycation, erythrocytes were incubated during 5 days in the absence or presence of increasing glucose concentrations up. HbA1c levels were first evaluated in our different fractions and pathological percentages were obtained for G137 erythrocytes (7%). Hence, our *in vitro* conditions represent an suitable glycation model inducing HbA1c percentages similar to those that can be measured in diabetic patients. Indeed, a HbA1c content of 6.5% corresponds to the threshold that is currently used to diagnose person with diabetes \[[@pone.0235335.ref027]\]. A more detailed characterization of our preparations at a molecular level, using mass spectrometry, revealed that erythrocytes incubated with 25 or 137 mM of glucose are significantly more glycated in both hemoglobin subunits (α and β) than erythrocytes incubated in the absence of glucose.

Analysis of erythrocyte morphology revealed a higher fragility (facilitated hemolysis), reduced size, and impaired deformability when glycated at 137mM of glucose. Glycated erythrocyte lysis, may constitute a source of oxidative stress through the high iron content in hemoglobin that could be released in the arterial wall vicinity \[[@pone.0235335.ref013]\]. Our cytometry results show altered erythrocyte size following *in vitro* glycation which is identical to observations made in aged and senescent erythrocytes. Erythrocyte size is a common biomarker used in clinical analysis and is reported as red blood cell width (RDW) \[[@pone.0235335.ref014]\]. Very recently, a positive association was found between RDW and the severity of coronary artery disease \[[@pone.0235335.ref014]\]. Ektacytometry is an adequate methodology to assess erythrocyte deformability \[[@pone.0235335.ref026]\]. Our data indicate that glycation phenomena induced by the hyperglycemic incubations render erythrocytes significantly less deformable and therefore more rigid than erythrocytes incubated under low glycemic conditions. Whilst ektacytometry is a well defined technique for the diagnosis of specific pathology, its use in research is less developed \[[@pone.0235335.ref026]\]. However, a recent research article published by the group of Pretorius showed a close link between erythrocyte deformability, hemorheology and cardiovascular dysfunction parameters \[[@pone.0235335.ref031]\]. The impaired capacity of erythrocytes to deform when glycated may have significant implications in the progression of vascular complications in diabetes. Indeed, *in vivo* glycated erythrocytes may exhibit an altered capacity to pass through tiny vessels like those present in intraplaque neovascularization, contributing to plaque progression and instability \[[@pone.0235335.ref015]\].

Oxidative stress and damage caused by ROS are implicated in the development of pathologies and in diabetes complications \[[@pone.0235335.ref004],[@pone.0235335.ref033]\]. In this study, enhanced ROS formation was observed in glycated erythrocytes, associated with a reduced peroxidase activity. Free radicals and oxidants such as O~2~°-, HO° and H~2~O~2~, may arise from the high oxygen pressure and from the iron present in hemoglobin \[[@pone.0235335.ref013]\]. In addition, the generation of reactive oxygen species observed in our glycated erythrocyte model could also result from glucose auto-oxidation \[[@pone.0235335.ref028]\]. Under our experimental conditions, decreased peroxidase activity lead to reduced H~2~O~2~ "detoxification" by catalysis to H~2~O. Hydrogen peroxide can generate the highly reactive hydroxyl radical HO° through Fenton reaction involving iron \[[@pone.0235335.ref007]\]. Similar results in term of oxidative stress has been observed in erythrocytes when isolated from insulin resistant obese children \[[@pone.0235335.ref034]\].

Oxidative stress can lead to the formation of oxidised compounds that may affect protein structure and function \[[@pone.0235335.ref035]\]. A significant accumulation of the oxidative biomarker 4-HNE was detected in erythrocytes glycated with 25 and 137 mM glucose ([Fig 4B and 4C](#pone.0235335.g004){ref-type="fig"}) and associated with a significant reduction in the chymotrypsin-like activity of the proteasome ([Table 3](#pone.0235335.t003){ref-type="table"}). If proteasome activity may be activated under moderate oxidative stress, in higher oxidant conditions a decrease in proteolytic activity may occur \[[@pone.0235335.ref032]\]. Friguet et al., identified the 4-hydroxynonenal (4-HNE) as a specific oxidant that can inhibit proteasome activity though its binding to the enzymatic protein complex \[[@pone.0235335.ref032]\]. Under our experimental conditions, the observed significant impairment in proteasome activity in glycated erythrocytes might result from the enhanced ROS formation and 4-HNE content present in our glycated erythrocyte preparations. This reduced proteasome activity may contribute to the altered redox status in G137 erythrocytes leading to increased oxidised protein accumulation. In addition, oxidised proteins that are not degraded by the impaired proteasome system may also contribute to the enhanced ROS generation in G137 erythrocytes. Enhanced 4-HNE accumulation in glycated erythrocytes may induce adduct formation in proteasome subunit leading to proteolytic activity inhibition \[[@pone.0235335.ref036]\]. If the proteasome plays an important role in controlling redox homeostasis and in degradation oxidised proteins \[[@pone.0235335.ref032]\], its activities in erythrocytes remain poorly studied. It is worth noting that in a recent study, using a proteomic analysis performed on blood, the 20 S proteasome was identified as a target for glycation in erythrocytes isolated from diabetic patients \[[@pone.0235335.ref037]\].

Phagocytosis experiments revealed significantly increased phagocytosis of *in vitro* glycated erythrocytes by endothelial cells. This phagocytosis was associated with a higher phosphatidylserine exposure at the surface of glycated erythrocytes attesting their enhanced eryptosis. Abnormal adherence and phagocytosis of erythrocytes by endothelial cells has been described in vascular complications such as atherosclerosis and abdominal aortic aneurysm \[[@pone.0235335.ref013],[@pone.0235335.ref016]\].

Most of the types of erythrocyte damage observed with *in vitro* glycated erythrocytes were also observed in erythrocytes isolated from diabetic patients. Indeed, an altered structure associated with enhanced ROS production and modified redox balance was observed in erythrocytes isolated from diabetic patients in comparison to those isolated from non-diabetics. Interestingly, an enhanced carbonylation of erythrocyte membranes were observed in cell isolated from diabetic patients and correlated with the clinical severity of the pathology \[[@pone.0235335.ref038]\]. Finally, the triggered eryptosis phenomenon observed in erythrocytes isolated from diabetics could lead to increased phagocytosis by endothelial cells *in vivo*.

Whilst more studies are needed to decipher the role of glycation on erythrocyte capacity in vascular dysfunctions linked to diabetes, the study presented here reveals several novel insights with respect to the impact of glycation on erythrocyte structure, morphology, and capacity to be phagocytosed by endothelial with a possible relevance to diabetes.
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###### Characterisation of glycation percentage in the different erythrocyte preparations by mass spectrometry.

Representative figures of the mass spectra obtained in three independent experiments for each incubation condition: 0 (G0), 5 (G5), 25 (G25) and 137 (G137) mmol/l glucose. On each spectrum, four main peaks were obtained corresponding to α-hemoglobin (αHb; 15130 Da), glycated α-hemoglobin (gαHb; 15330 Da), β-hemoglobin (βHb; 15890 Da), glycated β-hemoglobin (gβHb; 16100 Da).
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###### Diabetes alters erythrocyte morphology.

Typical Forward Scatter (FSC) and Side Scatter (SSC) characteristics represented in dot-blot graph obtained by cytometry erythrocytes from non diabetic (left) and diabetic persons (right).

(DOCX)

###### 

Click here for additional data file.
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:   advanced glycation (or glycoxidation) end products
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:   analysis of variance
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:   fluorescence-activated cell sorting

Flu-BA
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G~X~

:   erythrocytes incubated with × mM glucose

G~0~

:   incubated in the absence of glucose

4-HNE

:   4-hydroxynonenal

HT50

:   50% hemolysis time

MALDI

:   matrix-assisted laser desorption ionization

PBS

:   phosphate-buffered saline

ROS

:   reactive oxygen species
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We did ensure our manuscript meets PLOS ONE\'s style requirements including those for file naming.

2\. Ethics statement.

We did amend our current ethics statement to confirm that our study was specifically approved by the named institutional review board or ethics committee in the Methods section of our manuscript. Also, we added the same text to the "Ethics Statement" field of the submission form (via "Edit Submission").

3\. Acknowledgments Section.

Any funding-related text from the manuscript was removed.

Our funding statement was updated:
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6\. Supporting Information
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-Have the antibodies been validated for the dot blots and western blots? Were positive or negative controls performed?
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-It is interesting that the western blots showed an initial increase in AGEs following incubation with G5 and G25, but not with G137 whereas the dot blots showed significantly higher AGEs at G25 and G137.
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If significant increase AGE accumulation was measured by using dot blot for G25 and G137 compared with the control (Fig 1), the increase was significant when using western blot with G5 and G25, but not with G137 compared to the control (Fig S3). This slight difference in terms of statistical difference may arise from a more accurate quantification of dot blot signal than the signal quantification on western blot. Results in term of significant increase in AGE accumulation in our glycated erythrocyte preparations were comforted by different techniques, dot blot, western blot, mass spectrometry and also by the determination of glycated hemoglobin (% HbA1c), the 5-hydroxymethylfurfural and the early glycation product (EGP) levels.

-Line 247: These HT50 data are shown in figure 1C, not figure 3. It is interesting that the HT50 trend is no longer seen with the G137 dose. Might that be related to the loss of AGE increase at the highest dose as well?

Thank you for pointing this out to us. The figure number has been corrected.

We agree, HT50 trend is no longer seen with the G137 dose. As previously written, significant increases in AGE accumulation in our glycated erythrocyte preparation were comforted by different techniques, dot blot, western blot, mass spectrometry and also by the determination of glycated hemoglobin (% HbA1c), the 5-hydroxymethylfurfural and the early glycation product (EGP) levels. All data obtained, but western blot quantification, evidenced significant AGE accumulation increase for G137 samples compared to the control.

Hence, we would rather think that this lower capacity of G137 sample to resist to a free radical-induced hemolysis may come from AGE accumulation.

-Discussion material (references) should not appear in the results section of a manuscript. As currently written, the results section reads more like a combined results and discussion section. Justification for the various assays could also be moved to the methods describing them.

As suggested discussion material including references were moved to the method section.

-Line 277 mentions a progressive increase in DCF fluorescence. However, only the highest dose of glucose produced significantly greater fluorescence than G0. Therefore, I do not think one can conclude that the fluorescence was progressively increased.

We agree, we modified our text and removed the term \"progressive increase\".

-Line 288: mentions that peroxidase activity was significantly reduced in G137 cells compared to G25. However, the table indicates a significant difference between G137 and G0 cells.

Thank you for pointing this out to us, text was corrected.

-Figure S6 seems to show variability in the amount of glycation within the diabetic samples with only 2 showing increased glycation. Were these samples from 4 different subjects?

Yes, these samples were from 4 different subjects, 4 diabetic and 4 non-diabetic individuals.

If variability was observed in the amount of glycation within the diabetic samples (Fig S6), AGE quantification revealed a significantly higher accumulation in erythrocytes from diabetics compared to erythrocytes from non-diabetic individuals (Fig 4E).

-Line 330 mentions a significant reduction in SOD in the diabetic samples. However, this significance is not shown in table 4.

Thank you, our text was modified:

\"Although catalase and SOD activities appeared not to be significantly different between both groups (ND vs. D), a significant reduced peroxidase activity was measured in erythrocytes isolated from diabetic persons (table 4). This reduction in peroxidase activity, associated with high glucose concentration, could explain the enhanced ROS formation in erythrocytes isolated from diabetic persons.\"

-Lines 336-337: mentions that the phosphatidylserine exposure was significantly higher in diabetic samples. This conclusion cannot be made as the p-value was not significant (0.051). Moreover, the conclusion regarding this variable in the discussion is likewise an overstatement (lines 349-351).

We agree and therefore changed our text. Line 336 337 we wrote \"Erythrocytes from diabetic persons exhibit a tendency for a higher phosphatidylserine exposure than erythrocytes isolated from non-diabetic persons.\"

Lane 351 we wrote \" Furthermore, we highlight a potentially higher phosphatidylserine exposure of erythrocytes when glycated.\"

-It is interesting that the in vitro exposed cells showed reduced LLVY with glycation whereas this variable was increased in the diabetic samples. What could explain this difference? It appears the in vitro experiments do not accurately model this variable.

Yes, this is indeed very interesting!

We developed on this in the revised version of our MS. Briefly, if proteasome activity may be activated under moderate oxidative stress, in higher oxidant conditions a decrease in proteolytic activity may occur \[1\]. Friguet et al., identified the 4-hydroxynonenal (4-HNE) as a specific oxidant that can inhibit proteasome activity though its binding to the enzymatic protein complex \[1\].

In vitro, significant reduction in the chymotrypsin-like activity of the proteasome (LLVY) was associated with a significant accumulation of the oxidative biomarker 4-HNE in erythrocytes glycated with 25 and 137 mM glucose. In vivo, if oxidative stress was higher in erythrocytes from diabetics than from non-diabetics, no variation was measured in term of 4-HNE accumulation. We think that enhanced oxidative stress in in vivo glycated erythrocytes if significant may be moderate enough to trigger proteasome LLVY activation.

Minor Comments:

-Lines 100, 224: Did you mean "fructosamine" as opposed to "frutosamine"?

The text was corrected. Fructosamine correct term was used.

-Inter- and intra-assay coefficients were provided for the free radical-induced hemolysis test, but not for other assays.

Yes, all assays used in our study were validated with citations provided and we keep at heart to give maximum information about our techniques such as inter and intra coefficient assay, which we only have for the free radical-induced hemolysis test as it was developed and patented in my former research group \[2\]. This later citation is provided in the revised version of our MS.

-Have the SOD and catalase activity assays been previously validated? (ie. Provide citations)

Yes, SOD and catalase activity assays were previously validated. A citation of a very recent work published by our group was included in the new revised version of our MS: \[3\]

-What is meant by "fixed erythrocytes", line 168? Do you mean affixed to the plate?

After 24-hours of incubation with erythrocytes, endothelial cells were washed 3 times with PBS and treated with water for 3 minutes to induce lysis (by hypotonic shock) of any fixed erythrocytes at the cellular membrane surface and supernatant was discarded.

This text was included in the new version of our revised MS.

-Table 1 and figures should be able to stand alone from a paper. Please define G0, G5, G25, and G137 in the table legend.

This is an excellent suggestion. Our different erythrocyte preparations G0, G5, G25, and G137 are now defined in the table and figure legend in the revised version of our MS.

-Figure 2: The labelling is confusing as the group of 4 figures do not need separate A-D labels. Consider labeling A-D, simply "A".

We agree. Figure labelling was changed. Previous figure 2AD is now figure 2A and previous figure 2E is now figure 2B.

-Line 281-282: It is mentioned that 4-HNE was higher in G25 and G137 erythrocytes compared to G5. Were levels not also higher than G0?

Actually 4-HNE levels were significantly higher in G25 and G137 erythrocytes compared to G5.

-lines 362-363: "glycated erythrocyte lysis when glycated"??

Thank you, our text was corrected.

-Line 373: delete "Pr"

Text was corrected.

References:

1\. Friguet B (2006) Oxidized protein degradation and repair in ageing and oxidative stress. FEBS Lett 580: 2910-2916.
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Dear Dr. Bourdon,

Thank you for submitting your revised manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. These are minor revisions. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

We would appreciate receiving your revised manuscript by Jun 19 2020 11:59PM. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Ping Song, Ph.D

Academic Editor

PLOS ONE
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Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: All comments have been addressed

Reviewer \#2: (No Response)

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: No

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: No

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: (No Response)

Reviewer \#2: The highlight of this manuscript is relatively comprehensive comparison on the structure change, redox status and the EC phagocytosis of erythrocytes under the condition of glycation between in vivo and invitro. But there are still some parts needed to be improved and further explained. Some of the results showed opposite phonotype in in vitro and in vivo, which should be well discussed.

Majors:

In the hemolysis study, the results indicate that low concentrated glucose incubation had a protective membrane-stabilizing effect, which means an increased "flexibility" of the cell membrane or less fragile membrane. However, in the test of deformability, elongation index was reduced after glucose incubation, which suggests a reduced "flexibility" of the cell membrane and/or cytoskeleton. How does the authors explain these possible "conflict" phonotypes?

In some papers (for example PMID: 31704555), erythrocytes from diabetes showed impaired hemolysis resistance, which is opposite the phenomenon observed in this manuscript. Do the in vitro and in vivo glycations lead to different hemolysis results?

The high glucose concentration may change the osmolarity of the solution and making the solution hypertonic, therefore the cells may already in a shrank state in the initial stage, which may cause influence on the results. Did the authors detect the cell morphology with microscopy?

The proteasome activity detected in in vitro and in vivo showed opposite results in the manuscript. When treated with high glucose level, impaired proteasome activity was detected. But the proteasome activity from the diabetic erythrocytes showed an increased activity. How does the author explain these results?

Minors:

The data analysis used in Table2 & 3 should be One-way ANOVA.

If possible, can the author add the AOPP data back?

In the method section, water was used to induce lysis of the erythrocytes sticking on the surface of ECs. EC adhesion is not very strong. Does this method also wash away some EC and affect the quantification of internalized erythrocytes?

The figures need to be reorganized. The supplementary figures can be integrated in regular figure as well.

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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Majors:

In the hemolysis study, the results indicate that low concentrated glucose incubation had a protective membrane-stabilizing effect, which means an increased "flexibility" of the cell membrane or less fragile membrane. However, in the test of deformability, elongation index was reduced after glucose incubation, which suggests a reduced "flexibility" of the cell membrane and/or cytoskeleton. How does the authors explain these possible "conflict" phonotypes?

It is true, erythrocytes incubated with low glucose concentration exhibit an enhanced resistance to free radical-induced hemolysis concomitantly with an impaired flexibility of their membrane. Then, results obtained in the hemolysis and deformability tests may appear conflictual. Actually, these two tests did not assess the same biological phenomenon. Our in vitro free radical-induced blood hemolysis test allows determination of erythrocyte capacity to resist to an oxidative stress mediated by a free radical generator (AAPH), a chemical agent. Results were expressed as the half time of hemolysis (HT50) and reported on figure 2E.

The deformability of the different erythrocyte preparations was analysed by ektacytometry. This methodology allows elongation index determination, a biophysical index which expresses erythrocyte deformability capacity in response to increasing shear stress (Fig 2F and 2G).

Hence, if our "hemolysis test" measures erythrocyte capacity to resist to hemolysis when submitted to a free radical generator, elongation index specifically expresses membrane flexibility/rigidity. In other words, these two different methods give two types of results.

Concerning results, erythrocytes that have been incubated with high glucose concentrations exhibit both impaired hemolysis resistance capacity (2E) and reduced membrane flexibility (Fig 2F and 2G).

In some papers (for example PMID: 31704555), erythrocytes from diabetes showed impaired hemolysis resistance, which is opposite the phenomenon observed in this manuscript. Do the in vitro and in vivo glycations lead to different hemolysis results?

Thank you for mentioning this.

We agree, in some papers, erythrocytes from diabetes showed impaired hemolysis resistance. Please note, the mentioned reference (PMID: 31704555) is a recent article from our group. In this article, erythrocytes from diabetic patients exhibited a slight non-significant decrease in free radical-induced hemolysis half time in comparison with erythrocytes from non-diabetic (Cf fig A).

Figure 1 is issued from Catan et al (2019) Atherosclerosis.

Considering phenomenon observed in our present manuscript, if erythrocytes in vitro incubated with 5 or 25 mM of glucose (G5, G25) exhibited a higher HT50 compared to G0 (Figure 2E), those incubated with 137 mM of glucose (G137) do not exhibit such hemolysis resistance any more. In addition, HbA1c measurement in our in vitro glycated preparations revealed that values obtained for G137 erythrocytes (7%) were highly similar to HbA1c values observed in diabetic patients (table 1).

Hence, in our experimental conditions, in vitro and in vivo glycation lead to similar hemolysis results.

Finally, please note in our present study, a slight non-significant impairment in HT50 for erythrocytes was also observed when isolated from diabetics when compared to non-diabetic (Cf figure 2).

Figure 2. This figure was established with data from the present study.

The high glucose concentration may change the osmolarity of the solution and making the solution hypertonic, therefore the cells may already in a shrank state in the initial stage, which may cause influence on the results. Did the authors detect the cell morphology with microscopy?

It is true, high glucose concentration may change the osmolarity of the solution making cell potentially in a shrank state in the initial stage.

In our experimental conditions, we did not observe strong evidence of such phenomenon by microscopy (fig 3). If an increased number erythrocyte ghosts is observed when incubated with increasing glucose concentrations (see arrows), most erythrocytes does not exhibit a significant shrank state in relation to glucose concentration.

In addition, if such phenomenon would occur, please note our erythrocyte preparations used in the present MS, were washed in an isotonic solution prior analysis.

Figure 3. This figure corresponds to erythrocyte preparations that were incubated with 5 (A), 50 (B) or 100 (C) mM glucose for five days. Please note these preparations were not washed in an isotonic solution prior microscopic analysis. Bar corresponds to 10 µm.

The proteasome activity detected in in vitro and in vivo showed opposite results in the manuscript. When treated with high glucose level, impaired proteasome activity was detected. But the proteasome activity from the diabetic erythrocytes showed an increased activity. How does the author explain these results?

We agree with this and explanations are provided in our revised version of our MS.

Page 14 we wrote:

"Conversely, the chymotrypsin-like activity of the proteasome appeared to be significantly enhanced in erythrocytes purified from diabetics compared to those from non-diabetics (table 4). Proteasome activity may be activated under moderate oxidative stress \[1\]. In vivo, if oxidative stress is higher in erythrocytes from diabetics than from non-diabetics, no variation was measured in term of 4-HNE accumulation. Enhanced oxidative stress in in vivo glycated erythrocytes may be significant and moderate enough to trigger proteasome LLVY activation."

Minors:

The data analysis used in Table2 & 3 should be One-way ANOVA.

We followed Reviewer's advice and used One-way ANOVA for statistical analysis in table 2 and 3.

Modifications in the revised version of our MS were reported lines 236, 287 and 289.

If possible, can the author add the AOPP data back?

We followed Reviewer's advice, page 14 we wrote "In addition, accumulation of advanced oxidation product (AOPP), was found to be higher (+18%) in erythrocytes from diabetics but this increase did not reach significance."

In the method section, water was used to induce lysis of the erythrocytes sticking on the surface of ECs. EC adhesion is not very strong. Does this method also wash away some EC and affect the quantification of internalized erythrocytes?

Yes, we did use water to induce lysis of erythrocytes sticking on the surface of cultured endothelial cells. This method may indeed wash away some endothelial cells and such phenomenon was noticed when cells were treated with highly glycated erythrocytes. Still, this phenomenon could not affect our results since enhanced internalization of erythrocytes was significant and observed in endothelial cells that have been incubated with glycated erythrocytes. In addition, please note erythrocyte phagocytosis by endothelial cells was confirmed by recent unpublished data using flow cytometry and confocal microscopy. These results would be part of a future MS.

The figures need to be reorganized. The supplementary figures can be integrated in regular figure as well.

According to Reviewer's advice, our figures were reorganized in the new version of our MS.

Four previous supplementary figures are now integrated in regular figures in the present version of our MS.

It concerns:

\- Figure \#1 (previous figure S1): Early glycation product detection by using fluorescent boronic acids.

\- Figure 2C and 2D (previous figure S3): Enhanced AGE formation in glycated erythrocytes.

\- Figure 5E (previous figure S5): Enhanced oxidative stress in erythrocytes from diabetics.

\- Figure 5G (previous figure S6): Enhanced AGE content in erythrocytes from diabetics.

\[1\] Friguet, B. Oxidized protein degradation and repair in ageing and oxidative stress. FEBS Lett 580:2910-2916; 2006.
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Dear Dr. Bourdon,

We're pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you'll receive an e-mail detailing the required amendments. When these have been addressed, you'll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at <http://www.editorialmanager.com/pone/>, click the \'Update My Information\' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they'll be preparing press materials, please inform our press team as soon as possible \-- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

Kind regards,

Ping Song, Ph.D

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

The authors have addressed the concerns raised by two reviewers. The manuscript is acceptable in PLOS ONE.

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#2: All comments have been addressed

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#2: They authors have addressed all the comments. But the figures still need reorganization to be appropriated displayed in a printed page. A single figure should is composed of multiple well-arranged graphs. The authors\' figures still display as individual graph which does not meet the requirement of publication. Please look at the figure pattern in other published PLOS papers.
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7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#2: No
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Dear Dr. Bourdon:

I\'m pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they\'ll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

If we can help with anything else, please email us at <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Ping Song

Academic Editor

PLOS ONE
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